29 unknown, 12 completed, 7 not yet recruiting, 1 active not recruiting. 20 Phase 2, 17 Phase 1, 9 Not applicable, 2 Early Phase 1, 2 Phase 3.
Follow Fuzhou General Hospital: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SERS Sensor Based on CHA Reaction for EGFR Mutation Typing in Advanced Lung Cancer SERS sensor based on CHA reaction - Lung Cancer in Normal and Malignant Tumors | Not yet recruiting | Fuzhou General Hospital | 400 | 2026-05-01 | 2025-03-31 | |
| SERS-Based Serum Molecular Spectral Screening for Hematogenous Metastasis Serum Raman spectroscopy intelligent diagnostic system - Lung Cancers | Not yet recruiting | Fuzhou General Hospital | 200 | 2026-04-09 | 2025-03-31 | |
| SERS-Based Serum Molecular Spectral Screening for Benign and Malignant Pulmonary Proliferative Nodules Serum Raman spectroscopy intelligent diagnostic system - Lung Cancer in Normal and Malignant Tumors | Not yet recruiting | Fuzhou General Hospital | 200 | 2026-04-08 | 2025-03-31 | |
| SERS-Based Serum Molecular Spectral Screening for Lung Cancer Type Serum Raman spectroscopy intelligent diagnostic system - Lung Cancer, Non-Small Cell, Lung Cancer Small Cell Lung Cancer (SCLC) | Not yet recruiting | Fuzhou General Hospital | 223 | 2026-04-05 | 2025-03-31 | |
| SERS-Based Serum Molecular Spectral Detection of Invasive Lung Cancer Serum Raman spectroscopy intelligent diagnostic system - Lung Cancer Patients | Not yet recruiting | Fuzhou General Hospital | 200 | 2026-04-04 | 2025-03-31 | |
| Therapy for Advanced NSCLC With EGFR 19delins Mutation Icotinib/Gefitinib - Lung Cancer | Early Phase 1 | Not yet recruiting | Fuzhou General Hospital | 94 | 2026-03-30 | 2026-03-09 |
| Posterior Extra-fascial RARP in Intermediate or High Risk Prostate Cancer Extrafascial robotic assisted radical prostatectomy via posterior approach, Extrafascial robotic assisted radical prostatectomy via anterior approach - Surgical Procedure, Unspecified, Prostate Cancer | Not applicable | Active not recruiting | Ning Xu | 118 | 2025-11-01 | 2026-04-13 |
| Efficacy and Safety Analysis of First-Line ABCP Therapy in Advanced SMARCA4-Mutated NSCLC Atezolizumab+Bevacizumab+Carboplatin+Paclitaxel - Non Small Cell Lung Cancer | Not yet recruiting | Fuzhou General Hospital | 35 | 2025-08-20 | 2025-07-30 | |
| Defining COVID-19 Infection Severity on Presentation to Hospital Medical observation, Supportive treatment (BSC), Intensive care management - COVID-19, Infections | Unknown | Fuzhou General Hospital | 3000 | 2023-01-04 | 2023-01-10 | |
| The Efficacy and Safety of Azovudine in the Treatment of COVID-19 Azorubine - COVID-19, Infections | Unknown | Fuzhou General Hospital | 500 | 2023-01-04 | 2023-01-10 | |
| ctDNA as a Biomarker for Treatment in Advanced NSCLC Immunotherapy, Chemotherapeutic Agent, Chemotherapy - Non-small Cell Lung Cancer | Unknown | Fuzhou General Hospital | 500 | 2022-07-31 | 2022-08-04 | |
| Induction Tislelizumab Combined With Chemotherapy Followed by Definitive Chemoradiotherapy in the Treatment of Locally Unresectable Esophageal Squamous Cell Carcinoma Tislelizumab, Albumin paclitaxel, Nedaplatin - Immunotherapy Esophagus Cancer | Phase 2 | Recruiting | Fuzhou General Hospital | 93 | 2022-05-31 | 2024-02-07 |
| Peginterferon Alpha-2b Therapy in Chronic Hepatitis Patients With Normal ALT Level and Low Viremia Peginterferon alpha-2b, Nucleotide Analog, pulse peginterferon alpha-2b - Chronic Hepatitis B Patients With a Normal ALT Level and Low Viremia | Phase 1 / Phase 2 | Unknown | Fuzhou General Hospital | 300 | 2021-12-10 | 2022-01-24 |
| QYJD Compound Preparation Promotes Rapid Postoperative Recovery in Early-stage NSCLC Patients by Regulating Tissue Microecology: a Prospective, Randomized Controlled, Open-label, Phase I Clinical Study With Predefined Future Exploration QYJD Compound Preparation - NSCLC | Phase 1 | Completed | Fuzhou General Hospital | 15 | 2021-12-08 | 2025-01-09 |
| Camrelizumab Combined With Radiotherapy for Adjuvant Treatment of Esophageal Squamous Cell Carcinoma After Surgery Camrelizumab, radiotherapy - Esophageal Squamous Cell Carcinomas | Not applicable | Unknown | Fuzhou General Hospital | 20 | 2021-02-01 | 2021-02-05 |
| Camrelizumab Combined With Apatinib, Etoposide and Cisplatin Treat Small-cell Lung Cancer. Camrelizumab combined with Apatinib, Etoposide and Cisplatin - Lung Neoplasm, Small Cell Lung Cancer | Phase 3 | Unknown | Fuzhou General Hospital | 45 | 2020-08-01 | 2021-02-08 |
| Safety and Effectiveness of Mesenchymal Stem Cells in the Treatment of Pneumonia of Coronavirus Disease 2019 Oseltamivir, hormones, oxygen therapy - COVID-19 Pneumonia | Early Phase 1 | Unknown | Fuzhou General Hospital | 60 | 2020-03-01 | 2020-05-01 |
| Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer Pyrotinib, Trastuzumab, Aromatase Inhibitors - Breast Cancer Female, HER2-positive Breast Cancer | Phase 2 | Unknown | Fuzhou General Hospital | 77 | 2019-11-01 | 2019-09-12 |
| Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Patients With LA-NPC Nab-paclitaxel - Nasopharyngeal Carcinoma | Phase 2 | Unknown | Fuzhou General Hospital | 92 | 2019-07-09 | 2019-07-11 |
| A Multi-center Registry Study: The Follow-up the Complications for Trans-vaginal Mesh Surgery Pelvic Organ Prolapse | Unknown | Peking Union Medical College Hospital | 4147 | 2019-04-10 | 2019-07-23 |
Showing 20 of 52. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (4) · Diabetes Mellitus, Type 1 (4) · Lung Neoplasms (4) · COVID-19 (2) · Diabetes Mellitus, Type 2 (2) · Infections (2) · Neoplasms (2) · Pelvic Organ Prolapse (2) · Prostatic Hyperplasia (2) · Small Cell Lung Carcinoma (2) · Suicide, Assisted (2) · Uremia (2) · Breast Diseases (1) · Breast Neoplasms (1) · Carcinoma, Renal Cell (1)
apatinib (3) · Insulin (2) · Radiotherapy (2) · 130-nm albumin-bound paclitaxel (1) · Adrenal Cortex Hormones (1) · Anastrozole (1) · Angiotensin Receptor Antagonists (1) · Angiotensin-Converting Enzyme Inhibitors (1) · Antineoplastic Agents (1) · Aromatase Inhibitors (1) · Basiliximab (1) · Bortezomib (1) · COVID-19 Nucleic Acid Testing (1) · Cisplatin (1) · Combined Modality Therapy (1)
China (45)
Jianming Tan, professor (4) · Lan Zhu, MD (3) · Baosong Xie (1) · Chen Xi, PhD (1) · Chengping Hu (1) · Dongliangli Li, Dr. (1) · Feng Ye (1) · Guoxiang Lai (1) · Hong Xu, PhD (1) · Hong Yu (1) · Hongni Jiang (1) · Jianming Tan T Jianming, professor (1) · Jianming Tan Tan, M.D and Ph.D (1) · Jianming Tan, M.D and Ph.D (1)
PMID 15541456, PMID 18294347, PMID 18633105, PMID 19103734, PMID 19118301, PMID 19496761, PMID 19829730, PMID 19875806, PMID 20883559, PMID 21037431, PMID 21161683, PMID 21332580, PMID 21585547, PMID 21834917, PMID 22356343, PMID 22436957, PMID 22974955, PMID 22974956, PMID 24175245, PMID 24290656, PMID 24502959, PMID 24897036, PMID 25559146, PMID 26628416, PMID 32533785, PMID 33443938, PMID 33735608, PMID 33743213, PMID 34021265, PMID 34855502, PMID 34921135, PMID 34929158, PMID 34934198, PMID 35086778, PMID 35289632, PMID 38979743, PMID 39350270